Safety of Abciximab injection during endovascular treatment of ruptured aneurysms

dc.creatorGentric, Jean-Christophe
dc.creatorBrisson, Joelle
dc.creatorBatista, André Lima
dc.creatorGhostine, Jimmy
dc.creatorRaymond, Jean
dc.creatorRoy, Daniel
dc.creatorWeill, Alain
dc.date2023-05-17T19:37:10Z
dc.date2023-05-17T19:37:10Z
dc.date2015-05
dc.date.accessioned2023-09-04T12:45:34Z
dc.date.available2023-09-04T12:45:34Z
dc.identifierBATISTA, André Lima; et al. Safety of Abciximab injection during endovascular treatment of ruptured aneurysms. Interventional Neuroradiology, [S.L.], v. 21, n. 3, p. 332-336, 11 maio 2015. SAGE Publications. http://dx.doi.org/10.1177/1591019915582001.
dc.identifierhttps://repositorio.ufrn.br/handle/123456789/52469
dc.identifier10.1177/1591019915582001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8601929
dc.descriptionBackground and purpose: We aimed to determine the safety of intra-arterial Abciximab injection in the management of thromboembolic complications during endovascular treatment of ruptured cerebral aneurysms. Methods: In a monocentric consecutive series of endovascular treatment of 783 ruptured aneurysms, 42 (5.3%) patients received Abciximab after the aneurysm was secured. Bleeding complications were registered and dichotomized as follows: new intracranial hemorrhage and peripheral bleeding. For each patient, World Federation of Neurosurgery (WFNS) sub arachnoid hemorrhage (SAH) grade, shunting, and clinical outcomes in the post-operative period and at 3–6 months were recorded. Results: SAH WFNS grades were as follows: grade I n ¼ 14, grade II n ¼ 10, grade III n ¼ 11, grade IV n ¼ 4, grade V n ¼ 3. Ten patients had intracranial hematoma additionally to the SAH prior to embolization. Four patients (9.5%) presented more blood on the post-embolization CT but only one suffered a new clinically relevant intracranial hemorrhage. Two patients (4.8%) experienced significant peripheral bleeding but none were associated with long-term disabilities. Fourteen patients had a shunt installed less than 24 h prior to Abciximab injection and one less than 48 h later. At 3–6-month follow-up, 31 patients (74%) achieved a modified Rankin Scale score (mRS) of 2 or less, six patients (14%) had a mRS of 3–5, three were dead (7%), and two were lost at follow-up. Conclusion: When the aneurysm is secured, intra-arterial Abciximab injection is a low complication rate treatment modality for thromboembolic events during embolization of cerebral ruptured aneurysm
dc.languageen
dc.publisherInterventional Neuroradiology
dc.subjectsafety
dc.subjectabciximab
dc.subjectcerebral aneurysm
dc.subjectsubarachnoid hemorrhage
dc.subjectaneurysm coiling
dc.titleSafety of Abciximab injection during endovascular treatment of ruptured aneurysms
dc.typearticle


Este ítem pertenece a la siguiente institución